Human bone derived insulin like growth factor binding protein
CA 2107475 A1 · Owner: Roche Diagnostics Gmbh · Inventors: Mohan, Subburaman; Baylink, David J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Purified and isolated compositions of a binding protein for insulin-like growth factors (IGFs) I and II are provided. The binding protein, known as human bone derived IGF binding protein (hBD-IGFBP), potentiates the proliferative effects of IGF-II upon bone cells. Diagnostic assays are also provided for hBD-IGFBP as well, as pharmaceutical compositions and methods for treatment of bone disorders, wound healing, skin repair, and means for modulating IGF activity in bone.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 15, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 15, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 15, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.